Product Description
A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2; a pyridazine carboxamide-derived Tyk2 JH2 ligand as a clinical Tyk2 inhibitor currently in late development for the treatment of psoriasis (Sourced from: https://pubmed.ncbi.nlm.nih.gov/33370104/)
Mechanisms of Action: TYK2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Psoriasis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| IM016-006 | P1 |
Completed |
Psoriasis |
2016-12-15 |
2019-03-20 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
09/29/2023 |
News Article |
Lysophosphatidic Acid Receptor 1 Market Insights and Global Research and Clinical Survey Report 2023 to 2029 |
|
09/12/2023 |
News Article |
The Lysophosphatidic Acid Receptor 1 market is likely to witness significant competition tracking over the forecast period, with a projected CAGR of 4.7%. |
|
08/01/2023 |
PubMed |
Recent progress on tyrosine kinase 2 JH2 inhibitors. |
|
01/14/2021 |
PubMed |
Discovery of BMS-986202: A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2. |